Handelsbanken Fonder AB Sells 3,400 Shares of Elanco Animal Health Incorporated $ELAN

Handelsbanken Fonder AB cut its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 2.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 136,200 shares of the company’s stock after selling 3,400 shares during the quarter. Handelsbanken Fonder AB’s holdings in Elanco Animal Health were worth $1,945,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ELAN. Primecap Management Co. CA boosted its stake in shares of Elanco Animal Health by 3.1% in the 2nd quarter. Primecap Management Co. CA now owns 51,766,814 shares of the company’s stock worth $739,230,000 after buying an additional 1,543,279 shares during the last quarter. Traub Capital Management LLC bought a new stake in Elanco Animal Health during the second quarter worth $97,000. MTM Investment Management LLC lifted its holdings in Elanco Animal Health by 5.5% during the second quarter. MTM Investment Management LLC now owns 15,268 shares of the company’s stock worth $218,000 after acquiring an additional 800 shares during the period. Rockefeller Capital Management L.P. boosted its position in Elanco Animal Health by 23.1% in the second quarter. Rockefeller Capital Management L.P. now owns 74,094 shares of the company’s stock worth $1,058,000 after purchasing an additional 13,893 shares during the last quarter. Finally, Creative Planning grew its stake in Elanco Animal Health by 115.2% in the 2nd quarter. Creative Planning now owns 68,724 shares of the company’s stock valued at $981,000 after purchasing an additional 36,794 shares during the period. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Wall Street Analysts Forecast Growth

ELAN has been the topic of a number of recent analyst reports. Piper Sandler lifted their target price on Elanco Animal Health from $12.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, August 11th. Wall Street Zen raised shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 15th. Argus upgraded shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a research note on Wednesday, November 19th. Stifel Nicolaus increased their target price on shares of Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Finally, UBS Group lifted their price target on shares of Elanco Animal Health from $25.00 to $27.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $21.56.

Elanco Animal Health Price Performance

Shares of NYSE:ELAN opened at $23.36 on Thursday. The firm has a market capitalization of $11.61 billion, a PE ratio of 389.36, a P/E/G ratio of 3.18 and a beta of 1.71. The company has a quick ratio of 1.23, a current ratio of 2.40 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average price of $21.15 and a two-hundred day moving average price of $17.31. Elanco Animal Health Incorporated has a twelve month low of $8.02 and a twelve month high of $23.70.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. Elanco Animal Health’s revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.13 EPS. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS. Equities analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.